Anti-Acinetobacter baumannii development program
Using the proprietary discovery engine, PasNas, ABAC Therapeutics has generated a series of promising molecules that show good antibacterial activity against a panel of multi-drug resistant bugs and clinical isolates of Acinetobacter baumannii, and have an improved safety and efficacy profile in preclinical models, together with a novel mechanism of action.
Anti-Escherichia coli and anti-Klebsiella pneumoniae programs
Pathogen-specific compounds active against Escherichia coli and Klebsiella pneumoniae are being evaluated to select new leads.
The compounds generated in this programs demonstrate no cross-resistance with current antibiotics and therefore retain activity against strains harboring resistance mechanisms that inactivate many other marketed antibiotics.